



\*\*\*\*\*  
**KEIZAI SOCIETY U.S. - JAPAN BUSINESS FORUM**  
\*\*\*\*\*

---

## グローバル・バイオテック産業 将来の見通し

パネリスト:

**Dr. Roger Wyse**

*Managing Director and General Partner, Burrill & Company  
A member of Int'l Advisory Panel for Biotechnology for Malaysia's Prime Minister*

**Dr. Mary Haak-Frendscho**

*President and CSO, Takeda San Francisco*

**Dr. Akiko Futamura**

*President and CEO, InfiniteBio*

**Mr. Haru Morita**

*President and CEO, REGiMMUNE*

2010年10月28日(木)

登録およびネットワーキング: 5:30 – 6:00 p.m.

イベント: 6:00 – 8:00 p.m.

Wilson Sonsini Goodrich & Rosati (WSGR)  
650 Page Mill Road, Palo Alto, CA 94304

軽食とソフトドリンク

料金:

10/24 11:00pm までに登録の方: \$20

10/27 5:00pm までに登録の方: \$35

当日参加の方: \$50

(当日参加は歓迎しますが、席に限りがあります。)

服装: ビジネスカジュアル

経済ソサエティのウェブサイトで登録してください。 [www.keizai.org](http://www.keizai.org)

**Ustream**によるインターネットライブ放送

料金: 無料。10/26 5:00pm (日本時間 10/27 9:00am) までに登録してください。  
ご登録いただいた方には、インターネット放送の詳細を 10/27にお送りいたします。

## イベントの概略

サンフランシスコ・ベイエリアはバイオテクノロジーの革命発祥の地です。今回のフォーラムでは、バイオテック産業の将来の展望を探るべく、パネリストらが以下の問題について討議します：経済危機とその余波の影響を受けバイオテック産業における事業形態がいかに変化したか？新興マーケットが既存マーケットに与える影響は？注目すべき国境を越えた取引とは？今日のグローバル経済で成功する秘訣は？注目に値する優れたイニシアチブをとっている地方政府は？そのイニチアチブから学ぶべきことは何か？

パネルディスカッションの冒頭でAkiko Futamura氏にグローバル化された今日のバイオテック産業の概要を説明していただきます。バイオテック企業はどのような問題・課題に直面し、生き残り成功を掛け、いかなる努力を行っているのでしょうか。

Roger Wyse 氏には、増加し続ける食糧とエネルギーに対する需要をバイオテクノロジーの利用によりいかに満たすことができるかについて話していただきます。人口が急速に増加する中、この需要を満たすことは、地政学的な観点からも、経済的な観点からも、21世紀の最も重要な問題であり、多くの議論を呼んでいます。産業アプリケーション、世界の食糧安全保障、そして持続可能性はバイオテック産業でいかに展開されているのでしょうか。Dr. Wyse は顧問という立場で地方政府へのアドバイスをを行い、幅広い投資経験を有しています。プライベートセクターと共に増加し続ける食糧・エネルギーに対する需要を満たすばかりでなく、さらに一歩踏み出て業界のリーダーになろうというイニチアチブが政府組織に存在するなど、我々の政府組織に関する見方を一新するような議論をお楽しみください。

Dr. Mary Haak-Frendschoには、企業の観点から、世界的な経済危機を乗り越え将来的な成長をかけて大手バイオテック企業やバイオ医薬品メーカーが取っている事業戦略について話していただきます。R&Dの展望を踏まえ、米国がバイオテック産業のR&Dと製造において世界のリーダーであり続けているのかどうかを検討します。イノベーションとマネージメントがいかに国境を越えて実践され、企業の生き残りを左右しているのでしょうか？

Haru Morita 氏にはその奥深い経験に基づき、産業が不況から回復する中でスタートアップ会社が直面するであろうリスクあるいは事業チャンスについて話していただきます。さらに、市場機会と規制プロセスの観点から、海外のスタートアップ会社が米国で事業を行うにあたり享受できる利点を他国との比較で議論します。

経済ソサイエティの2010年のテーマは「Catch the Next Wave – New Opportunities for 2010」です。このフォーラムは、世界経済がどのように不況から回復し、次の波にのり、そして、次々にやってくる新しいチャンスを掴むのかに焦点を当てて開催しています。名刺をたくさんお持ちになり、イベントの参加者と名刺を交換してください。苦境の時期は、ネットワークや助け合いが重要です。Next Waveの力を拡散するために、このメールを知り合いの方に転送してください。



**Dr. Roger Wyse** is a Managing Director and General Partner at Burrill & Company, a leading Life Sciences company with \$1 billion in venture capital under management, with businesses in merchant banking, private equity and media. Dr. Wyse joined Burrill in 1998 and has led the development of Burrill & Company's agriculture, nutraceuticals, health & wellness, and industrial biotechnology related activities in venture capital investing. In this endeavor he pioneered the "Virtual Corporate Venture" model and has attracted over 40 corporate investors into the various Burrill funds. Dr Wyse chairs or serves on the boards of 11 private companies. He is Co-Chairman of the \$150M Malaysian Life Capital Fund and is a member of the International Advisory Panel for Biotechnology (BioIAP) for the Prime Minister of Malaysia. He was founder and Chairman of the Alliance for Animal Genome

Research. He serves on the Board of Industrial Section of BIO. Dr. Wyse is a sought after speaker on biotechnology applications and policy in food, agricultural and bio-clean-technology. He has over 30 years of experience as an internationally recognized scientist and as a Dean at two major research universities; Rutgers and the University of Wisconsin-Madison. Immediately prior to joining Burrill & Company, Dr. Wyse served for 5 years as Dean of the College of Agricultural and Life Sciences at the University of Wisconsin-Madison. From 1986 – 1992, he served as Dean of Research at Rutgers University. In research, Dr. Wyse earned international recognition for his basic studies in plant biochemistry. He published over 150 scientific papers. In recognition of his research accomplishments he received the prestigious Arthur Flemming Award in 1982 as the Outstanding Young Scientist in the US Federal Service. He was elected a Fellow of the American Association for the Advancement of Science, the Crop Science Society of America and The American Society of Agronomy. He also served as a consultant to numerous Fortune 500 companies.



**Dr. Mary Haak-Frendscho** is President and Chief Scientific Officer of Takeda San Francisco. She established Takeda's new center of excellence for biologics, which also serves as the therapeutic antibody (Ab) IND engine for Takeda Pharmaceutical Company, Japan's largest biopharmaceutical and biotech company. Dr. Haak-Frendscho leads the overall Ab target discovery, Ab drug discovery, and preclinical development activities for oncology, inflammatory and metabolic candidate medicines. In addition, she is responsible for actively expanding Takeda's US science, business, and intellectual property presence in the Biotech sector. Dr. Haak-Frendscho has nearly 20 years of industry experience at companies including Genentech, Abgenix and XOMA. She is an inventor on over 25 issued and pending patents, authored about 70 scientific articles, and has an adjunct appointment at the University of Wisconsin where she obtained her PhD.



**Dr. Akiko Futamura** is President and CEO of InfiniteBio. Formerly, she was Executive Vice President, Science and Technology/Business Development at SC BioScience USA, a subsidiary of Sumitomo Corporation, and Vice President, Science and Technology at Summit Biotech, a venture capital arm of Sumitomo Corporation. She was responsible for identifying key technologies, conducting due diligence and was involved in business development at therapeutics and platform (tool) companies. She played a key role in concluding a number of important alliances and investments with companies such as Morphotek, Cytellect, QuantumDot Corporation, Xenogen, Panomics and Multispan. At

InfiniteBio, Dr. Futamura has assisted numerous Japanese companies commercialize novel *in vitro* and *in vivo* technologies in the U.S., including PhoenixBio, SCIVAX Corporation, and ReproCELL. Dr. Futamura received her BS in biotechnology from the University of Tokyo, and Ph.D. in biochemistry from the University of Illinois. She is currently serving as a visiting professor at Osaka University, Japan, and is working to transfer novel technologies from Japan to the U.S. Dr. Futamura is a co-founder of the Japanese Scientists Network in the U.S.



**Mr. Haru Morita** has served as President, CEO and Director of REGiMMUNE, which is headquartered in Japan but has a US subsidiary in Mountain View, California. Mr. Morita has been with REGiMMUNE since founding it in 2006 and has raised over US\$20 million two years ago. Prior to REGiMMUNE, Mr. Morita served on the management teams of Y's Therapeutics, Ltd. and Y's Therapeutics, Inc., most recently as Director of Business Development with responsibility for corporate planning as well. Mr. Morita's professional experience also includes management consulting at Booz Allen and Hamilton (Tokyo office).

In this capacity as consultant, he helped clients to establish and implement strategy not only in pharmaceutical business but also in other area such as chemical and consumer products. Prior to that, Mr. Morita worked as a research scientist in the medical research division of Kirin Brewery Co. Ltd (lately it merged into Kyowa-Hakko-Kirin). At Kirin he was part of the research and development team that was first to clone Megakaryocyte Growth and Differentiation Factor (MDGF or Thrombopoietin). Mr. Morita received both of his BS in Chemical Engineering and MS in Molecular and Cellular Biology from the University of Tokyo.

*Keizai Society wishes to thank its sponsors:*

**Intrax Cultural Exchange**

**Wilson Sonsini Goodrich & Rosati**

**Tazan International**

**USAsia Venture Partners**

**Fenwick & West**

**ZL Technologies**

**SunBridge**

**Union Bank**